Prenyltransferase inhibitors: Treating human ailments from cancer to parasitic infections

MedChemComm

Volumn 4, Issue 3, 2013, Pages 476-492

  Ochocki, Joshua D ^a   Distefano, Mark D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 2 PHOSPHONO 3 (3 PYRIDINYL)PROPANOIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BISPHOSPHONIC ACID DERIVATIVE; DIMETHYLALLYLTRANSFERASE; GGTI 2154; GGTI 2418; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; ISOPRENOID; ISOPRENOID DERIVATIVE; L 778123; LONAFARNIB; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PRAVASTATIN; PRENYLTRANSFERASE INHIBITOR; RAS PROTEIN; RISEDRONIC ACID; SCH 211618; TIPIFARNIB; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING AFFINITY; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; COVALENT BOND; DELTA AGENT HEPATITIS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HEPATITIS C; HUMAN; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROGERIA; PROTEIN PRENYLATION; PROTEIN PROCESSING; REVIEW;

EID: 84874505210     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c2md20299a     Document Type: Review

References (146)

1. C. C. Farnsworth S. L. Wolda M. H. Gelb J. A. Glomset Human lamin B contains a farnesylated cysteine residue J. Biol. Chem. 1989 264 20422 20429
2. C. C. Farnsworth M. H. Gelb J. A. Glomset Identification of geranylgeranyl-modified proteins in HeLa cells Science 1990 247 320 322
3. W. Benetka M. Koranda F. Eisenhaber Protein prenylation: an (almost) comprehensive overview on discovery history, enzymology, and significance in physiology and disease Monatsh. Chem. 2006 137 1241 1281
4. P. J. Casey Biochemistry of protein prenylation J. Lipid Res. 1992 33 1731 1740
5. S. Clarke Protein isoprenylation and methylation at carboxyl-terminal cysteine residues Annu. Rev. Biochem. 1992 61 355 386
6. N. Berndt A. D. Hamilton S. M. Sebti Targeting protein prenylation for cancer therapy Nat. Rev. Cancer 2011 11 775 791
7. J. L. Hougland K. A. Hicks H. L. Hartman R. A. Kelly T. J. Watt C. A. Fierke Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities J. Mol. Biol. 2010 395 176 190
8. J. L. Hougland C. L. Lamphear S. A. Scott R. A. Gibbs C. A. Fierke Context-dependent substrate recognition by protein farnesyltransferase Biochemistry 2009 48 1691 1701
9. C. L. Lamphear, E. A. Zverina, J. L. Hougland and C. A. Fierke, Global identification of protein prenyltransferase substrates: defining the prenylated proteome, 2011, vol. 29, pp. 207-234
10. I. Jordens M. Marsman C. Kuijl J. Neefjes Rab proteins, connecting transport and vesicle fusion Traffic 2005 6 1070 1077
11. E. A. Stigter, G. Triola, R. S. Goody and H. Waldmann, Inhibition of Rab prenylation, Elsevier, 2011, vol. 30, pp. 179-203
12. L. Desnoyers J. S. Anant M. C. Seabra Geranylgeranylation of Rab proteins Biochem. Soc. Trans. 1996 24 699 703
13. M. R. Lackner R. M. Kindt P. M. Carroll K. Brown M. R. Cancilla C. Chen H. de Silva Y. Franke B. Guan T. Heuer T. Hung K. Keegan J. M. Lee V. Manne C. O'Brien D. Parry J. J. Perez-Villar R. K. Reddy H. Xiao H. Zhan M. Cockett G. Plowman K. Fitzgerald M. Costa P. Ross-Macdonald Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors Cancer Cell 2005 7 325 336
14. J. S. Taylor T. S. Reid K. L. Terry P. J. Casey L. S. Beese Structure of mammalian protein geranylgeranyltransferase type-I EMBO J. 2003 22 5963 5974
15. S. B. Porter E. R. Hildebrandt S. R. Breevoort D. Z. Mokry T. M. Dore W. K. Schmidt Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones Biochim. Biophys. Acta 2007 1773 853 862
16. F. Ghomashchi X. Zhang L. Liu M. H. Gelb Binding of prenylated and polybasic peptides to membranes: affinities and intervesicle exchange Biochemistry 1995 34 11910 11918
17. M. C. Seabra Membrane association and targeting of prenylated Ras-like GTPases Cell. Signalling 1998 10 167 172
18. W. W. Epstein D. Lever L. M. Leining E. Bruenger H. C. Rilling Quantitation of prenylcysteines by a selective cleavage reaction Proc. Natl. Acad. Sci. U. S. A. 1991 88 9668 9670
19. R. Roskoski Jr Protein prenylation: a pivotal posttranslational process Biochem. Biophys. Res. Commun. 2003 303 1 7
20. P. J. Casey P. A. Solski C. J. Der J. E. Buss p21ras is modified by a farnesyl isoprenoid Proc. Natl. Acad. Sci. U. S. A. 1989 86 8323 8327
21. J. H. Jackson C. G. Cochrane J. R. Bourne P. A. Solski J. E. Buss C. J. Der Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation Proc. Natl. Acad. Sci. U. S. A. 1990 87 3042 3046
22. H.-W. Park S. R. Boduluri J. F. Moomaw P. J. Casey L. S. Beese Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution Science 1997 275 1800 1805
23. 2+- farnesyltransferase indicates metal coordination of the substrate thiolate J. Biol. Chem. 1997 272 20 23
24. as of peptide substrates bound as zinc thiolates Biochemistry 1999 38 13138 13146
25. V. A. Clausen R. L. Edelstein M. D. Distefano Stereochemical analysis of the reaction catalyzed by human protein geranylgeranyl transferase Biochemistry 2001 40 3920 3930
26. R. L. Edelstein V. A. Weller M. D. Distefano J. S. Tung Stereochemical analysis of the reaction catalyzed by yeast protein farnesyltransferase J. Org. Chem. 1998 63 5298 5299
27. J. M. Dolence C. D. Poulter A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase Proc. Natl. Acad. Sci. U. S. A. 1995 92 5008 5011
28. Y. Mu C. A. Omer R. A. Gibbs On the stereochemical course of human protein-farnesyl transferase J. Am. Chem. Soc. 1996 118 1817 1823
29. S. Lenevich J. Xu A. Hosokawa C. J. Cramer M. D. Distefano Transition state analysis of model and enzymatic prenylation reactions J. Am. Chem. Soc. 2007 129 5796 5797
30. J. E. Pais K. E. Bowers C. A. Fierke Measurement of the α-secondary kinetic isotope effect for the reaction catalyzed by mammalian protein farnesyltransferase J. Am. Chem. Soc. 2006 128 15086 15087
31. M.-H. Ho V. M. De P. M. Dal M. L. Klein Unraveling the catalytic pathway of metalloenzyme farnesyltransferase through QM/MM computation J. Chem. Theory Comput. 2009 5 1657 1666
32. J. S. Pickett K. E. Bowers H. L. Hartman H.-W. Fu A. C. Embry P. J. Casey C. A. Fierke Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation Biochemistry 2003 42 9741 9748
33. Y. Yang B. Wang M. N. Ucisik G. Cui C. A. Fierke K. M. Merz Insights into the mechanistic dichotomy of the protein farnesyltransferase peptide substrates CVIM and CVLS J. Am. Chem. Soc. 2012 134 820 823
34. K. Alexandrov, Y. Wu, W. Blankenfeldt, H. Waldmann and R. S. Goody, Organization and function of the rab prenylation and recycling machinery, in Enzymes, ed., C. A. H. Fuyuhiko Tamanoi, and, O. B. Martin, Academic Press, 2011, vol. 29, pp. 147-162
35. Z. Guo Y.-W. Wu D. Das C. Delon J. Cramer S. Yu S. Thuns N. Lupilova H. Waldmann L. Brunsveld R. S. Goody K. Alexandrov W. Blankenfeldt Structures of RabGGTase-substrate/product complexes provide insights into the evolution of protein prenylation EMBO J. 2008 27 2444 2456
36. A. J. Krzysiak D. S. Rawat S. A. Scott J. E. Pais M. Handley M. L. Harrison C. A. Fierke R. A. Gibbs Combinatorial modulation of protein prenylation ACS Chem. Biol. 2007 2 385 389
37. Y.-C. Wang M. D. Distefano Solid-phase synthesis of C-terminal peptide libraries for studying the specificity of enzymatic protein prenylation Chem. Commun. 2012 48 8228 8230
38. T. C. Turek-Etienne C. L. Strickland M. D. Distefano Biochemical and structural studies with prenyl diphosphate analogues provide insights into isoprenoid recognition by protein farnesyl transferase Biochemistry 2003 42 3716 3724
39. O. Pylypenko A. Rak R. Reents A. Niculae V. Sidorovitch M.-D. Cioaca E. Bessolitsyna N. H. Thoma H. Waldmann I. Schlichting R. S. Goody K. Alexandrov Structure of Rab escort protein-1 in complex with Rab geranylgeranyltransferase Mol. Cell 2003 11 483 494
40. U. T. T. Nguyen Z. Guo C. Delon Y. Wu C. Deraeve B. Franzel R. S. Bon W. Blankenfeldt R. S. Goody H. Waldmann D. Wolters K. Alexandrov Analysis of the eukaryotic prenylome by isoprenoid affinity tagging Nat. Chem. Biol. 2009 5 227 235
41. F. Tamanoi Inhibitors of ras farnesyltransferases Trends Biochem. Sci. 1993 18 349 353
42. M. Schlitzer, R. Ortmann and M. Altenkämper, CaaX-protein prenyltransferase inhibitors, in Drug Design of Zinc-Enzyme inhibitors, John Wiley & Sons, Inc., 2009, pp. 813-857
43. A. J. Wiemer J. S. Yu L. W. Shull R. J. Barney B. M. Wasko K. M. Lamb R. J. Hohl D. F. Wiemer Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation Bioorg. Med. Chem. 2008 16 3652 3660
44. S. A. Holstein C. L. Wohlford-Lenane R. J. Hohl Isoprenoids influence expression of Ras and Ras-related proteins Biochemistry 2002 41 13698 13704
45. M. Schlitzer Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors Curr. Pharm. Des. 2002 8 1713 1722
46. F. P. Coxon M. H. Helfrich B. Larijani M. Muzylak J. E. Dunford D. Marshall A. D. McKinnon S. A. Nesbitt M. A. Horton M. C. Seabra F. H. Ebetino M. J. Rogers Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages J. Biol. Chem. 2001 276 48213 48222
47. Z. Guo Y.-W. Wu K.-T. Tan R. S. Bon E. Guiu-Rozas C. Delon U. T. Nguyen S. Wetzel S. Arndt R. S. Goody W. Blankenfeldt K. Alexandrov H. Waldmann Development of selective RabGGTase inhibitors and crystal structure of a RabGGTase-inhibitor complex Angew. Chem., Int. Ed. 2008 47 3747 3750
48. S. Halazy J. P. Gotteland M. Lamothe D. Perrin B. T. Hill Rationally designed FPTase inhibitors Drugs Future 1997 22 1133 1146
49. C. J. Dinsmore I. M. Bell Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity Curr. Top. Med. Chem. 2003 3 1075 1093
50. R. A. Gibbs T. J. Zahn J. S. Sebolt-Leopold Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms Curr. Med. Chem. 2001 8 1437 1465
51. P. Gilleron R. Millet R. Houssin N. Wlodarczyk A. Farce A. Lemoine J. F. Goossens P. Chavatte N. Pommery J. P. Henichart Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential farnesyltransferase inhibitors: an approach to new lead compounds Eur. J. Med. Chem. 2006 41 745 755
52. A. Vogt Y. Qian M. A. Blaskovich R. D. Fossum A. D. Hamilton S. M. Sebti A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing J. Biol. Chem. 1995 270 660 664
53. N. E. Kohl F. R. Wilson S. D. Mosser E. Giuliani S. J. DeSolms M. W. Conner N. J. Anthony W. J. Holtz R. P. Gomez et al., Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice Proc. Natl. Acad. Sci. U. S. A. 1994 91 9141 9145
54. E. C. Lerner Y. Qian M. A. Blaskovich R. D. Fossum A. Vogt J. Sun A. D. Cox C. J. Der A. D. Hamilton S. M. Sebti Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes J. Biol. Chem. 1995 270 26802 26806
55. E. C. Lerner Y. Qian A. D. Hamilton S. M. Sebti Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor J. Biol. Chem. 1995 270 26770 26773
56. D. J. Augeri S. J. O'Connor D. Janowick B. Szczepankiewicz G. Sullivan J. Larsen D. Kalvin J. Cohen E. Devine H. Zhang S. Cherian B. Saeed S.-C. Ng S. Rosenberg Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase J. Med. Chem. 1998 41 4288 4300
57. M. L. Curtin A. S. Florjancic J. Cohen W.-Z. Gu D. J. Frost S. W. Muchmore H. L. Sham Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase Bioorg. Med. Chem. Lett. 2003 13 1367 1371
58. D. C. Beshore I. M. Bell C. J. Dinsmore C. F. Homnick J. C. Culberson R. G. Robinson C. Fernandes E. S. Walsh M. T. Abrams H. G. Bhimnathwala J. P. Davide M. S. Ellis-Hutchings H. A. Huber K. S. Koblan C. A. Buser N. E. Kohl R. B. Lobell I. W. Chen D. A. McLoughlin T. V. Olah S. L. Graham G. D. Hartman T. M. Williams Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase Bioorg. Med. Chem. Lett. 2001 11 1817 1821
59. M. Liu M. S. Bryant J. Chen S. Lee B. Yaremko P. Lipari M. Malkowski E. Ferrari L. Nielsen N. Prioli J. Dell D. Sinha J. Syed W. A. Korfmacher A. A. Nomeir C.-C. Lin L. Wang A. G. Taveras R. J. Doll F. G. Njoroge A. K. Mallams S. Remiszewski J. J. Catino V. M. Girijavallabhan P. Kirschmeier W. R. Bishop Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice Cancer Res. 1998 58 4947 4956
60. C. L. Strickland P. C. Weber W. T. Windsor Z. Wu H. V. Le M. M. Albanese C. S. Alvarez D. Cesarz J. del Rosario J. Deskus A. K. Mallams F. G. Njoroge J. J. Piwinski S. Remiszewski R. R. Rossman A. G. Taveras B. Vibulbhan R. J. Doll V. M. Girijavallabhan A. K. Ganguly Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships J. Med. Chem. 1999 42 2125 2135
61. J. Sun M. A. Blaskovich D. Knowles Y. Qian J. Ohkanda R. D. Bailey A. D. Hamilton S. M. Sebti Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I Cancer Res. 1999 59 4919 4926
62. H. Peng D. Carrico V. Thai M. Blaskovich C. Bucher E. E. Pusateri S. M. Sebti A. D. Hamilton Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I Org. Biomol. Chem. 2006 4 1768 1784
63. M. Watanabe H. D. G. Fiji L. Guo L. Chan S. S. Kinderman D. J. Slamon O. Kwon F. Tamanoi Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds J. Biol. Chem. 2008 283 9571 9579
64. K. W. Cheng J. P. Lahad W.-l. Kuo A. Lapuk K. Yamada N. Auersperg J. Liu K. Smith-McCune K. H. Lu D. Fishman J. W. Gray G. B. Mills The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers Nat. Med. 2004 10 1251 1256
65. W.-W. Dong Q. Mou J. Chen J.-T. Cui W.-M. Li W.-H. Xiao Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma World J. Gastroenterol. 2012 18 1806 1813
66. K. Croizet-Berger C. Daumerie M. Couvreur P. J. Courtoy M.-F. van den Hove The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production Proc. Natl. Acad. Sci. U. S. A. 2002 99 8277 8282
67. G. A. Rodan A. A. Reszka Bisphosphonate mechanism of action Curr. Mol. Med. 2002 2 571 577
68. A. A. Reszka G. A. Rodan Bisphosphonate mechanism of action Curr. Rheumatol. Rep. 2003 5 65 74
69. A. A. Reszka G. A. Rodan Nitrogen-containing bisphosphonate mechanism of action Mini-Rev. Med. Chem. 2004 4 711 719
70. F. P. Coxon F. H. Ebetino E. H. Mules M. C. Seabra C. E. McKenna M. J. Rogers Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo Bone 2005 37 349 358
71. F. P. Coxon K. Thompson M. J. Rogers Recent advances in understanding the mechanism of action of bisphosphonates Curr. Opin. Pharmacol. 2006 6 307 312
72. M. S. Marma Z. Xia C. Stewart F. Coxon J. E. Dunford R. Baron B. A. Kashemirov F. H. Ebetino J. T. Triffitt R. G. G. Russell C. E. McKenna Synthesis and biological evaluation of α-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate J. Med. Chem. 2007 50 5967 5975
73. R. A. Baron R. Tavare A. C. Figueiredo K. M. Blazewska B. A. Kashemirov C. E. McKenna F. H. Ebetino A. Taylor M. J. Rogers F. P. Coxon M. C. Seabra Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase J. Biol. Chem. 2009 284 6861 6868
74. R. S. Bon Z. Guo E. A. Stigter S. Wetzel S. Menninger A. Wolf A. Choidas K. Alexandrov W. Blankenfeldt R. S. Goody H. Waldmann Structure-guided development of selective RabGGTase inhibitors Angew. Chem., Int. Ed. 2011 50 4957 4961
75. W. R. Schafer R. Kim R. Sterne J. Thorner S. H. Kim J. Rine Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans Science 1989 245 379 385
76. J. L. Bos Ras oncogenes in human cancer: a review Cancer Res. 1989 49 4682 4689
77. Y. Reiss J. L. Goldstein M. C. Seabra P. J. Casey M. S. Brown Inhibition of purified p21ras farnesylprotein transferase by Cys-AAX tetrapeptides Cell 1990 62 81 88
78. E. C. Lerner T.-T. Zhang D. B. Knowles Y. Qian A. D. Hamilton S. M. Sebti Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene 1997 15 1283 1288
79. C. A. Rowell J. J. Kowalczyk M. D. Lewis A. M. Garcia Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo J. Biol. Chem. 1997 272 14093 14097
80. J. Sun Y. Qian A. D. Hamilton S. M. Sebti Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts Oncogene 1998 16 1467 1473
81. D. B. Whyte P. Kirschmeier T. N. Hockenberry I. Nunez-Oliva L. James J. J. Catino W. R. Bishop J.-K. Pai K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J. Biol. Chem. 1997 272 14459 14464
82. N. E. Kohl C. A. Omer M. W. Conner N. J. Anthony J. P. Davide S. J. deSolms E. A. Giuliani R. P. Gomez S. L. Graham et al., Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nat. Med. 1995 1 792 797
83. D. W. End G. Smets A. V. Todd T. L. Applegate C. J. Fuery P. Angibaud M. Venet G. Sanz H. Poignet S. Skrzat A. Devine W. Wouters C. Bowden Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res. 2001 61 131 137
84. W. R. Bishop R. Bond J. Petrin L. Wang R. Patton R. Doll G. Njoroge J. Catino J. Schwartz et al., Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells J. Biol. Chem. 1995 270 30611 30618
85. J. T. Hunt C. Z. Ding R. Batorsky M. Bednarz R. Bhide Y. Cho S. Chong S. Chao J. Gullo-Brown P. Guo S. H. Kim F. Y. F. Lee K. Leftheris A. Miller T. Mitt M. Patel B. A. Penhallow C. Ricca W. C. Rose R. Schmidt W. A. Slusarchyk G. Vite V. Manne Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4- ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity J. Med. Chem. 2000 43 3587 3595
86. C. A. Buser C. J. Dinsmore C. Fernandes I. Greenberg K. Hamilton S. D. Mosser E. S. Walsh T. M. Williams K. S. Koblan High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123 Anal. Biochem. 2001 290 126 137
87. Clinical trials using farnesyltransferase inhibitors, http://www.clinicaltrials.gov, accessed July 2012
88. A. T. Baines D. Xu C. J. Der Inhibition of Ras for cancer treatment: the search continues Future Med. Chem. 2011 3 1787 1808
89. R. Kurzrock H. M. Kantarjian J. E. Cortes N. Singhania D. A. Thomas E. F. Wilson J. J. Wright E. J. Freireich M. Talpaz S. M. Sebti Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Blood 2003 102 4527 4534
90. L. Sepp-Lorenzino Z. Ma E. Rands N. E. Kohl J. B. Gibbs A. Oliff N. Rosen A peptidomimetic inhibitor of farnesylprotein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines Cancer Res. 1995 55 5302 5309
91. L. N. Chan C. Hart L. Guo T. Nyberg B. S. J. Davies L. G. Fong S. G. Young B. J. Agnew F. Tamanoi A novel approach to tag and identify geranylgeranylated proteins Electrophoresis 2009 30 3598 3606
92. G. Charron L. K. Tsou W. Maguire J. S. Yount H. C. Hang Alkynyl-farnesol reporters for detection of protein S-prenylation in cells Mol. BioSyst. 2011 7 67 73
93. A. J. DeGraw C. Palsuledesai J. D. Ochocki J. K. Dozier S. Lenevich M. Rashidian M. D. Distefano Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation Chem. Biol. Drug Des. 2010 76 460 471
94. Y. Kho S. C. Kim C. Jiang D. Barma S. W. Kwon J. Cheng J. Jaunbergs C. Weinbaum F. Tamanoi J. Falck Y. Zhao A tagging-via-substrate technology for detection and proteomics of farnesylated proteins Proc. Natl. Acad. Sci. U. S. A. 2004 101 12479 12484
95. F. O. Onono M. A. Morgan H. P. Spielmann D. A. Andres T. Subramanian A. Ganser C. W. M. Reuter A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting Mol. Cell. Proteomics 2010 9 742 751
96. J. M. Troutman M. J. Roberts D. A. Andres H. P. Spielmann Tools to analyze protein farnesylation in cells Bioconjugate Chem. 2005 16 1209 1217
97. A. F. H. Berry W. P. Heal A. K. Tarafder T. Tolmachova R. A. Baron M. C. Seabra E. W. Tate Rapid multilabel detection of geranylgeranylated proteins by using bioorthogonal ligation chemistry ChemBioChem 2010 11 771 773
98. S. Reddy L. Comai Lamin A, farnesylation and aging Exp. Cell Res. 2012 318 1 7
99. R. C. M. Hennekam Hutchinson-Gilford progeria syndrome: review of the phenotype Am. J. Med. Genet., Part A 2006 140 2603 2624
100. S.-G. A. De R. Bernard P. Cau C. Navarro J. Amiel I. Boccaccio S. Lyonnet C. L. Stewart A. Munnich M. M. Le N. Levy Lamin A truncation in Hutchinson-Gilford progeria Science 2003 300 2055
101. M. Eriksson W. T. Brown L. B. Gordon M. W. Glynn J. Singer L. Scott M. R. Erdos C. M. Robbins T. Y. Moses P. Berglund A. Dutra E. Pak S. Durkin A. B. Csoka M. Boehnke T. W. Glover F. S. Collins Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome Nature 2003 423 293 298
102. H. J. Worman Prelamin A prenylation and the treatment of progeria J. Lipid Res. 2010 51 223 225
103. W. R. Bishop, R. Doll and P. Kirschmeier, Farnesyl transferase inhibitors: from targeted cancer therapeutic to a potential treatment for progeria, in Enzymes, 2011, vol. 29, pp. 275-303
104. H. J. Worman L. G. Fong A. Muchir S. G. Young Laminopathies and the long strange trip from basic cell biology to therapy J. Clin. Invest. 2009 119 1825 1836
105. R. D. Goldman D. K. Shumaker M. R. Erdos M. Eriksson A. E. Goldman L. B. Gordon Y. Gruenbaum S. Khuon M. Mendez R. Varga F. S. Collins Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome Proc. Natl. Acad. Sci. U. S. A. 2004 101 8963 8968
106. L. G. Fong D. Frost M. Meta X. Qiao S. H. Yang C. Coffinier S. G. Young A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of Progeria Science 2006 311 1621 1623
107. S. H. Yang M. O. Bergo J. I. Toth X. Qiao Y. Hu S. Sandoval M. Meta P. Bendale M. H. Gelb S. G. Young L. G. Fong Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation Proc. Natl. Acad. Sci. U. S. A. 2005 102 10291 10296
108. S. H. Yang M. Meta X. Qiao D. Frost J. Bauch C. Coffinier S. Majumdar M. O. Bergo S. G. Young L. G. Fong A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation J. Clin. Invest. 2006 116 2115 2121
109. S. H. Yang X. Qiao L. G. Fong S. G. Young Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation Biochim. Biophys. Acta 2008 1781 36 39
110. S. H. Yang S. Y. Chang D. A. Andres H. P. Spielmann S. G. Young L. G. Fong Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria J. Lipid Res. 2010 51 400 405
111. I. Varela S. Pereira A. P. Ugalde C. L. Navarro M. F. Suarez P. Cau J. Cadinanos F. G. Osorio N. Foray J. Cobo C. F. de N. Levy J. M. P. Freije C. Lopez-Otin Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging Nat. Med. 2008 14 767 772
112. M. Gerhard-Herman L. B. Smoot N. Wake M. W. Kieran M. E. Kleinman D. T. Miller A. Schwartzman A. Giobbie-Hurder D. Neuberg L. B. Gordon Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome Hypertension 2012 59 92 97
113. M. A. Merideth L. B. Gordon S. Clauss V. Sachdev A. C. M. Smith M. B. Perry C. C. Brewer C. Zalewski H. J. Kim B. Solomon B. P. Brooks L. H. Gerber M. L. Turner D. L. Domingo T. C. Hart J. Graf J. C. Reynolds A. Gropman J. A. Yanovski M. Gerhard-Herman F. S. Collins E. G. Nabel R. O. Cannon, III W. A. Gahl W. J. Introne Phenotype and course of Hutchinson-Gilford progeria syndrome N. Engl. J. Med. 2008 358 592 604
114. Phase II trial of lonafarnib (a farnesyltransferase inhibitor) for progeria, http://www.clinicaltrials.gov, accessed July 2012
115. L. B. Gordon M. E. Kleinman D. T. Miller D. S. Neuberg A. Giobbie-Hurder M. Gerhard-Herman L. B. Smoot C. M. Gordon R. Cleveland B. D. Snyder B. Fligor W. R. Bishop P. Statkevich A. Regen A. Sonis S. Riley C. Ploski A. Correia N. Quinn N. J. Ullrich A. Nazarian M. G. Liang S. Y. Huh A. Schwartzman M. W. Kieran Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome Proc. Natl. Acad. Sci. U. S. A. 2012
116. Study of zoledronic acid, pravastatin, and lonafarnib for patients with progeria, http://www.clinicaltrials.gov, accessed July 2012
117. V. M. Zhang M. Chavchich N. C. Waters Targeting protein kinases in the malaria parasite: update of an antimalarial drug target Curr. Top. Med. Chem. 2012 12 456 472
118. J. M. Kraus H. B. Tatipaka S. A. McGuffin N. K. Chennamaneni M. Karimi J. Arif C. L. M. J. Verlinde F. S. Buckner M. H. Gelb Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery J. Med. Chem. 2010 53 3887 3898
119. F. S. Buckner R. T. Eastman J. L. Nepomuceno-Silva E. C. Speelmon P. J. Myler V. W. C. Van K. Yokoyama Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major Mol. Biochem. Parasitol. 2002 122 181 188
120. H. Field I. Blench S. Croft M. C. Field Characterisation of protein isoprenylation in procyclic form Trypanosoma brucei Mol. Biochem. Parasitol. 1996 82 67 80
121. M. Ibrahim N. Azzouz P. Gerold R. T. Schwarz Identification and characterisation of Toxoplasma gondii protein farnesyltransferase Int. J. Parasitol. 2001 31 1489 1497
122. M. Kumagai A. Makioka T. Takeuchi T. Nozaki Molecular cloning and characterization of a protein farnesyltransferase from the enteric protozoan parasite Entamoeba histolytica J. Biol. Chem. 2004 279 2316 2323
123. H. D. Lujan M. R. Mowatt G.-Z. Chen T. E. Nash Isoprenylation of proteins in the protozoan Giardia lamblia Mol. Biochem. Parasitol. 1995 72 121 127
124. D. Carrico J. Ohkanda H. Kendrick K. Yokoyama M. A. Blaskovich C. J. Bucher F. S. Buckner V. W. C. Van D. Chakrabarti S. L. Croft M. H. Gelb S. M. Sebti A. D. Hamilton In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability Bioorg. Med. Chem. 2004 12 6517 6526
125. L. Nallan K. D. Bauer P. Bendale K. Rivas K. Yokoyama C. P. Horney P. P. Rao D. Floyd L. J. Lombardo D. K. Williams A. Hamilton S. Sebti W. T. Windsor P. C. Weber F. S. Buckner D. Chakrabarti M. H. Gelb V. W. C. Van Protein farnesyltransferase inhibitors exhibit potent antimalarial activity J. Med. Chem. 2005 48 3704 3713
126. J. Wiesner K. Kettler J. Sakowski R. Ortmann A. M. Katzin E. A. Kimura K. Silber G. Klebe H. Jomaa M. Schlitzer Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo Angew. Chem., Int. Ed. 2003 43 251 254
127. K. Yokoyama P. Trobridge F. S. Buckner J. Scholten K. D. Stuart V. W. C. Van M. H. Gelb The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth Mol. Biochem. Parasitol. 1998 94 87 97
128. S. Fletcher C. G. Cummings K. Rivas W. P. Katt C. Horney F. S. Buckner D. Chakrabarti S. M. Sebti M. H. Gelb V. W. C. Van A. D. Hamilton Potent, plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation J. Med. Chem. 2008 51 5176 5197
129. M. A. Hast C. B. Nichols S. M. Armstrong S. M. Kelly H. W. Hellinga J. A. Alspaugh L. S. Beese Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens J. Biol. Chem. 2011 286 35149 35162
130. M. A. Hast S. Fletcher C. G. Cummings E. E. Pusateri M. A. Blaskovich K. Rivas M. H. Gelb W. C. Van Voorhis S. M. Sebti A. D. Hamilton L. S. Beese Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase Chem. Biol. 2009 16 181 192
131. R. T. Eastman F. S. Buckner K. Yokoyama M. H. Gelb V. W. C. Van Fighting parasitic disease by blocking protein farnesylation J. Lipid Res. 2006 47 233 240
132. V. J. Bulbule K. Rivas C. L. M. J. Verlinde V. W. C. Van M. H. Gelb 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability J. Med. Chem. 2008 51 384 387
133. S. Olepu P. K. Suryadevara K. Rivas K. Yokoyama C. L. M. J. Verlinde D. Chakrabarti V. W. C. Van M. H. Gelb 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials Bioorg. Med. Chem. Lett. 2008 18 494 497
134. S. Duez L. Coudray E. Mouray P. Grellier J. Dubois Towards the synthesis of bisubstrate inhibitors of protein farnesyltransferase: synthesis and biological evaluation of new farnesylpyrophosphate analogues Bioorg. Med. Chem. 2010 18 543 556
135. E. Wong V. Okhonin M. V. Berezovski T. Nozaki H. Waldmann K. Alexandrov S. N. Krylov Inject-Mix-React-Separate-and-Quantitate (IMReSQ) method for screening enzyme inhibitors J. Am. Chem. Soc. 2008 130 11862 11863
136. G. Gupta H. Qin J. Song Intrinsically unstructured domain 3 of hepatitis C virus NS5A forms a fuzzy complex with VAPB-MSP domain which carries ALS-causing mutations PLoS One 2012 7 e39261
137. V. Lohmann F. Korner J.-O. Koch U. Herian L. Theilmann R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999 285 110 113
138. J. Ye C. Wang R. Sumpter M. S. Brown J. L. Goldstein M. Gale Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc. Natl. Acad. Sci. U. S. A. 2003 100 15865 15870
139. A. Ciancio M. Rizzetto Hepatitis: PEG-IFN for the treatment of hepatitis D Nat. Rev. Gastroenterol. Hepatol. 2011 8 304 306
140. J. C. Otto P. J. Casey The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells J. Biol. Chem. 1996 271 4569 4572
141. B. B. Bordier P. L. Marion K. Ohashi M. A. Kay H. B. Greenberg J. L. Casey J. S. Glenn A prenylation inhibitor prevents production of infectious hepatitis delta virus particles J. Virol. 2002 76 10465 10472
142. J. S. Glenn J. C. Marsters, Jr H. B. Greenberg Use of a prenylation inhibitor as a novel antiviral agent J. Virol. 1998 72 9303 9306
143. C. E. Walters G. Pryce D. J. R. Hankey S. M. Sebti A. D. Hamilton D. Baker J. Greenwood P. Adamson Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis J. Immunol. 2002 168 4087 4094
144. F. P. Coxon M. H. Helfrich H. R. Van't S. Sebti S. H. Ralston A. Hamilton M. J. Rogers Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298 J. Bone Miner. Res. 2000 15 1467 1476
145. M. A. Vallim L. Fernandes J. A. Alspaugh The RAM1 gene encoding a protein-farnesyltransferase α-subunit homologue is essential in Cryptococcus neoformans Microbiology 2004 150 1925 1935
146. L. M. Work A. R. McPhaden N. J. Pyne S. Pyne R. M. Wadsworth C. L. Wainwright Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty Circulation 2001 104 1538 1543